Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | GALR3 | O60755 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986625 | 0.94 | RAB9A (0.72) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2983653 | 0.94 | RAB9A (0.71) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2990405 | 0.93 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2990296 | 0.93 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2992805 | 0.93 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2983674 | 0.93 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2986536 | 0.93 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL31515434 | 0.91 | CYP2C9 (0.74) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8501307 | 0.91 | CYP2C9 (0.74) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2990343 | 0.91 | RAB9A (0.77) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61050979-A | — | — | None | — | — | JP | disclosed |
| US-8778975-B2 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion | Link Geonomics, Inc. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20100173944-A1 | HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION | ARIGEN PHARMACEUTICALS, INC. (JP) | 2010-07-08 | — | — | US | disclosed |
| EP-0175464-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION | Takeda Chemical Industries, Ltd. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4727150-A | ANTIULCER AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| EP-0175464-A1 | Benzimidazole derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1986-03-26 | — | — | EP | disclosed |
| JP-S6150979-A | PYRIDINE DERIVATIVE AND PREPARATION THEREOF | TAKEDA CHEM IND LTD | 1986-03-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173944-A1 | HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION | GIPR, PGC, SLC10A2 | RAB9A 198/4885NPC1 1869/4885CYP2C9 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.